Andrew Zhu on Atezolizumab/Bevacizumab in HCC – The ASCO Post
AACR Virtual Annual Meeting 2020 Andrew X. Zhu, MD, PhD, of Massachusetts General Hospital, discusses an exploratory analysis seeking to identify tumor-based molecular biomarkers that may be associated with clinical response or resistance to the combination treatment of atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma…